Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer
Federman, Noah, McDermott, RayLanguage:
english
Journal:
Expert Review of Clinical Pharmacology
DOI:
10.1080/17512433.2019.1661775
Date:
August, 2019
File:
PDF, 1.45 MB
english, 2019